Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Casi Pharmaceuticals Inc (CASI)

Casi Pharmaceuticals Inc (CASI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Casi Pharmaceuticals Inc 1701-1702 China Central Office Tower 1 No. 81 Jianguo Road Chaoyang District Beijing F4 100025 CHN

www.casipharmaceuticals.com P: 86-10-6508-6063

Description:

CASI Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the acquisition, development and commercialization of proprietary therapeutics for the treatment of cancer and other diseases for the global markets, with a focus on China. The Company's products present antiangiogenic solutions to cancer, cardiovascular disease, and macular degeneration. CASI Pharmaceuticals Inc., formerly known as EntreMed, Inc., is headquartered in Rockville, Maryland.

Key Statistics

Overview:

Market Capitalization, $K 30,822
Enterprise Value, $K 32,642
Shares Outstanding, K 13,401
Annual Sales, $ 33,880 K
Annual Net Income, $ -26,940 K
Last Quarter Sales, $ 6,030 K
Last Quarter Net Income, $ -5,480 K
EBIT, $ -25,080 K
EBITDA, $ -21,340 K
% of Insider Shareholders 21.24%
% of Institutional Shareholders 22.23%
Float, K 10,555
% Float 78.76%
Short Volume Ratio 0.46

Growth:

1-Year Return -14.84%
3-Year Return -87.15%
5-Year Return -93.05%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 41.88%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.29 on 03/28/24
Latest Earnings Date 05/15/24
Earnings Per Share ttm -1.86
EPS Growth vs. Prev Qtr 17.14%
EPS Growth vs. Prev Year 79.86%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 06/02/22

CASI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -77.55%
Return-on-Assets % -30.64%
Profit Margin % -79.52%
Debt/Equity 0.78
Price/Sales 0.97
Price/Cash Flow N/A
Price/Book 1.38
Book Value/Share 1.81
Interest Coverage -0.25
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar